Drug Monograph

Drug/Drug Class: **Avonex® (Interferon beta-1a) prefilled IM pen/ Immunomodulating Interferon beta Agent**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each single use prefilled pen (auto injector) of Avonex® for IM injection contains 30mcg of interferon beta-1a, 0.79 mg Sodium Acetate Trihydrate, USP; 0.25 mg Glacial Acetic Acid, USP; 15.8 mg Arginine Hydrochloride, USP; and 0.025 mg Polysorbate 20 in Water for Injection, USP. Each pen 0.5 mL for IM injection.
Manufacturer:	Biogen Idec Inc., Cambridge, MA 02142
Indications:	Avonex® (Interferon beta-1a) is indicated for the management of patients with relapsing types of multiple sclerosis to delay the onset of physical disability and reduce the occurrence of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been proven consist of patients who have MRI features consistent with multiple sclerosis and have experienced a first clinical event
Costs:	$ 3575.40 per Avonex® auto injector pen. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) and has preferred status.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Clinical Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ Preferred Agent ☐ Appropriate Indications ☐ PA Required

Prepared By: David J. Baker, Pharm. D. candidate.
Date: July 17, 2012